University of Michigan at ENA 2026

Nov 18–20, 2026 Barcelona, Spain ~1.5k attendees Website

University of Michigan brings 4 presentations to ENA 2026 in Barcelona. Its posters cover the discovery of new protein degraders and molecular glues for cancer targets. They include SD-1240, a clinical candidate STAT3 PROTAC degrader, pan-KRAS PROTACs with sub-nanomolar potency, and RPT04402, a molecular glue activator for PPP2R1A mutant cancers.

Organization	ENA 2026 Attendance
University of Michigan Ann Arbor, MI
umich.edu Universities & institutes Public research university in Ann Arbor whose Rogel Cancer Center runs cancer research and clinical care.	Poster Thu Nov 19 9:30–10am 1–3pm 4:30–5pm Part of Poster session: Drug Design Discovery of JZY3032, a First-in-Class DALTAC Rewiring AR-p300 Demonstrate Lineage-Selective Anti-tumor Efficacy in Advance Prostate Cancer Models Drug design Poster Thu Nov 19 9:30–10am 1–3pm 4:30–5pm Part of Poster session: Molecular Targeted Agents CRBN-Based Pan-KRAS PROTAC Degraders with Sub-Nanomolar Potency and Broad In Vivo Efficacy Across Clinically Relevant KRAS Mutant Tumors Targeted agents Poster Thu Nov 19 9:30–10am 1–3pm 4:30–5pm Part of Poster session: Molecular Targeted Agents Discovery of clinical candidate SD-1240, a potent and selective STAT3 PROTAC degrader Targeted agents Poster Fri Nov 20 10:45–11:15am 1:30–3pm Part of Poster session: New drugs Discovery of RPT04402, a first-in-class molecular glue activator with potent and selective anti-tumor activity in PPP2R1A mutant cancers Drug design

Organization

ENA 2026 Attendance

University of Michigan

Ann Arbor, MI

umich.edu

Universities & institutes

Public research university in Ann Arbor whose Rogel Cancer Center runs cancer research and clinical care.

Poster

Thu Nov 19
9:30–10am
1–3pm
4:30–5pm

Part of Poster session: Drug Design

Discovery of JZY3032, a First-in-Class DALTAC Rewiring AR-p300 Demonstrate Lineage-Selective Anti-tumor Efficacy in Advance Prostate Cancer Models

Drug design